alpha-PiHP Stats & Data

Potent NPS stimulant of the pyrrolidinophenone family closely related to α‑PVP/α‑PHP; typically appears as white/off‑white powder or crystals. Batch potency varies widely across vendors and time—use a 0.001 g scale, allergy test (≈1 mg), and incremental titration. Vaporization has the fastest onset and the highest redose liability; many users report compulsive re‑hitting leading to binges, sleep loss, and anxiety spikes. Insufflation is commonly described as notably caustic to nasal mucosa, with increasing irritation and nosebleeds across a session; post‑use saline rinses and spacing lines reduce harm. Cardiovascular strain (tachycardia, hypertension), vasoconstriction (cold extremities), hyperthermia with exertion, and severe insomnia are the most common acute risks; avoid heat, hydrate with electrolytes, and rest. If anxious or paranoid, reduce stimulation, cool down, and consider non‑sedating de‑escalation first; if a benzodiazepine is used, avoid redoses and combining with other depressants due to blackout/respiratory risk. Set a pre‑commitment: cap session total and stop‑time to disrupt redosing loops—many binges escalate after the first hour. Adulteration/misrepresentation occurs in street pills/powders; use reagent tests and, where possible, submit samples to a lab‑based drug checking service. Extended binges increase risk of psychosis‑like symptoms; sleep, nutrition, and at least several days of abstinence are protective. Data on human pharmacokinetics is sparse; avoid frequent reuse within the same week to limit tolerance and sleep debt.